Target Identification
What Is Target Identification?
Target identification involves molecular biology methods to screen disease-related proteins or genes, assessing their potential as drug targets. The process aims to discover disease-specific proteins/genes and manipulate their functions for therapeutic effects. Key steps include:
- Protein expression quantification: Proteomics techniques to detect abnormally expressed proteins in disease tissues
- Functional validation: Confirm candidate targets' pathological roles
- Drug binding analysis: Assessing small molecule/antibody affinity and selectivity for targets
Protein Array Services for Target Identification
- Accelerates drug development timelines: High-throughput protein chips enable rapid screening of thousands of targets, reducing early-stage selection time
- Reduces failure risk: Multi-marker detection (e.g., phosphorylation/methylation analysis) evaluates target feasibility, avoiding arbitrary drug design
- Supports personalized therapy: Identifies tumor-specific signaling pathway molecules for precision medicine marker development
- Optimizes resource allocation: Automated high-throughput platforms lower per-sample costs, ideal for large-scale screening
This process integrates bioinformatics prediction, experimental validation, and clinical collaboration to ensure targets have clinical translation potential. For example, our protein chips rapidly identify tumor growth signaling pathway molecules, aiding antineoplastic drug development.
Array Example
| Panel / Focus | Example Marker / Feature Combination | Target Application | Possible Sample Preparation |
| A. Differential Expression Profiling | - Tumor vs. normal arrays: surface antigens (EGFR, PD-L1, HER2), intracellular oncoproteins (RAS, BRAF), secreted markers (VEGF, TGF-β) - Disease vs. healthy in other conditions (e.g., inflammatory tissues vs. healthy controls) | 1. Identify proteins overexpressed in diseased vs. healthy tissues for potential targeting 2. Distinguish candidate drug targets that are highly or uniquely expressed in specific cell types or tissues | - In vitro: Compare lysates from disease-model cell lines vs. normal cell lines - In vivo: Tissue or serum samples from diseased animals or patients, comparing matched healthy controls; measure expression changes across multiple proteins |
| B. Phosphorylation & Activation Status | - Phospho arrays: p-ERK, p-Akt, p-STAT3, p-Src, p-MEK, p-FAK, p-EGFR - Kinases known to drive disease progression (e.g., c-Met, FGFR, JAK2) or novel kinases uncovered in advanced screens | 1. Pinpoint hyperactivated signaling nodes (e.g., over-phosphorylated kinases) as potential drug targets 2. Prioritize interventions aimed at blocking the most deregulated pathways | - In vitro: Cell lysates from disease vs. normal lines under serum-starved vs. stimulated conditions - In vivo: Tumor or affected tissue homogenates with phosphatase inhibitors; measure p-kinase vs. total kinase |
| C. Cell-Surface / Secretome Discovery | - Surface receptor arrays: integrins, GPCRs, CD markers, RTKs, co-stimulatory molecules - Secreted proteins: cytokines, growth factors, proteases, insulin-like growth factors (IGFs) | 1. Identify readily druggable targets (antibody-based, small molecules) on cell surfaces 2. Find biomarkers or targetable secreted factors that drive pathology | - In vitro: Conditioned media from disease-model cells or purified membrane fractions - In vivo: Serum/plasma, or partial membrane extracts from tissues, to see which surface/secreted proteins are upregulated |
| D. Protein–Ligand Interaction Arrays | - Arrays with large sets of potential binding proteins (e.g., kinases, transcription factors, metabolizing enzymes), tested against a labeled small-molecule library or a known "bait" compound | 1. Discover which proteins bind or respond to a candidate drug or probe 2. Define off-target or on-target binding events that may be therapeutically relevant | - In vitro: Spot potential target proteins, incubate with labeled drug candidate or library of small molecules - In vivo: Tissue lysates labeled or fractionated, though typically the arrays are used in vitro for direct binding detection |
| E. Comparative Disease Model Arrays | - Pathway-focused arrays for MAPK, PI3K/Akt, NF-κB, JAK/STAT - Tissue-specific arrays (e.g., neuro, cardiac, immune sets) | 1. Contrast normal vs. disease model (transgenic mouse, patient xenograft) to see which pathways are most upregulated 2. Highlight targets that are consistently altered across multiple models/replicates | - In vitro: Lysates from genetically modified cell lines (overexpressing or knockout for certain genes) - In vivo: Tissue extracts from transgenic or xenograft models at different disease stages, plus healthy controls |
Protein Array's Near-Infrared Microarray Protein Chip Technology Platform
Protein Array offers a cutting-edge near-infrared microarray protein chip technology platform that enhances the capabilities of Target Identification. Our platform combines laser confocal imaging, near-infrared fluorescence labeling, and special functional silicone membranes for high-throughput, multi-parameter detection with cost efficiency.
The feature of our Target Identification services at Protein Array include:
- High-throughput detection: Simultaneously analyzes multiple signaling pathways to elucidate complex pathological mechanisms
- Multi-parameter analysis: Detects phosphorylation, methylation, and other modifications alongside expression levels for comprehensive molecular networks
- Cost-effectiveness: Batch-produced chips reduce per-sample costs, suitable for large-scale screens
Applications of Target Identification
- Oncology drug screening: Identifies tumor-specific protein expression to guide small molecule/antibody drug development
- Signaling pathway research: Elucidates molecular mechanisms behind tumor growth, migration, and apoptosis
- Biomarker development: Screens proteins for clinical diagnostic utility
By integrating advanced technologies, our target identification platform not only accelerates drug development timelines but also reveals complex pathological mechanisms through high-throughput detection and multi-parameter analysis. This innovative solution reduces R&D costs while enabling seamless transitions from basic research to clinical applications, providing global oncology research institutions with efficient, precise molecular analysis tools.
- Custom Protein Arrays
- Drug Screening and Toxicity Assessment
- Immunoprofiling
- Oncology Drug Screening
- Signaling Pathway Analysis
- Spatial Multi-Omics and Targeted Proteomics
- Vaccine Development
- Antibody Profiling
- Protein-Protein Interaction Studies
- Allergen Screening
- Protein-Nucleic Acid Interaction Analysis